Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Invitae Publishes First Validation Data on MRD Assays, Laying Path to Future Clinical Expansion
Premium
The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
The company realized Q2 revenues from a recent surge in carrier testing volumes and expressed confidence in the potential inclusion of MRD testing in NCCN guidelines.
The company said it expects to launch a first version of its residual cancer test, OncoDetect, by the end of this year, while ongoing studies explore newer technology.
Natera Sues NeoGenomics for Patent Infringement
Natera alleges that NeoGenomics is infringing on two patents related to the Signatera minimal residual disease testing platform.